AU2003235913A1 - Cyanopyrrolidine derivatives - Google Patents

Cyanopyrrolidine derivatives

Info

Publication number: AU2003235913A1
Authority: AU; Australia
Prior art keywords: cyanopyrrolidine derivatives; cyanopyrrolidine; derivatives
Prior art date: 2002-05-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2003235913A

Inventor

Hiroshi Fukushima

Akira Hiratate

Kazuya Kameo

Masato Takahashi

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Taisho Pharmaceutical Co Ltd

Original Assignee

Taisho Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-05-09

Filing date

2003-05-09

Publication date

2003-11-11

2003-05-09 Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd

2003-11-11 Publication of AU2003235913A1 publication Critical patent/AU2003235913A1/en

Status Abandoned legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Diabetes (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AU2003235913A 2002-05-09 2003-05-09 Cyanopyrrolidine derivatives Abandoned AU2003235913A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2002-134421		2002-05-09
JP2002134421		2002-05-09
PCT/JP2003/005813 WO2003095425A1 (en)	2002-05-09	2003-05-09	Cyanopyrrolidine derivatives

Publications (1)

Publication Number	Publication Date
AU2003235913A1 true AU2003235913A1 (en)	2003-11-11

Family

ID=29416708

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2003235913A Abandoned AU2003235913A1 (en)	2002-05-09	2003-05-09	Cyanopyrrolidine derivatives

Country Status (3)

Country	Link
JP (1)	JPWO2003095425A1 (en)
AU (1)	AU2003235913A1 (en)
WO (1)	WO2003095425A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE60222667T2 (en)	2001-06-27	2008-07-17	Smithkline Beecham Corp.	FLUORPYRROLIDINES AS DIPEPTIDYLPEPTIDASE INHIBITORS
EP1627870A1 (en) *	2003-05-15	2006-02-22	Taisho Pharmaceutical Co., Ltd	Cyanofluoropyrrolidine derivative
CN101684089A (en)	2004-02-05	2010-03-31	杏林制药株式会社	bicycloester derivative
PT1753748E (en)	2004-05-12	2009-08-28	Pfizer Prod Inc	Proline derivatives and their use as dipeptidyl peptidase iv inhibitors
DOP2006000008A (en)	2005-01-10	2006-08-31	Arena Pharm Inc	COMBINED THERAPY FOR THE TREATMENT OF DIABETES AND RELATED AFFECTIONS AND FOR THE TREATMENT OF AFFECTIONS THAT IMPROVE THROUGH AN INCREASE IN THE BLOOD CONCENTRATION OF GLP-1
KR20080000665A (en)	2005-04-22	2008-01-02	알란토스 파마슈티컬즈 홀딩, 인코포레이티드	Dipeptidyl Peptidase-IV Inhibitors
WO2007102286A1 (en)	2006-03-08	2007-09-13	Kyorin Pharmaceutical Co., Ltd.	Method for producing aminoacetylpyrrolidinecarbonitrile derivative and production intermediate thereof
PE20071221A1 (en)	2006-04-11	2007-12-14	Arena Pharm Inc	GPR119 RECEPTOR AGONISTS IN METHODS TO INCREASE BONE MASS AND TO TREAT OSTEOPOROSIS AND OTHER CONDITIONS CHARACTERIZED BY LOW BONE MASS, AND COMBINED THERAPY RELATED TO THESE AGONISTS
EP2123636B1 (en)	2007-03-22	2012-03-21	Kyorin Pharmaceutical Co., Ltd.	Method for producing aminoacetylpyrrolidinecarbonitrile derivative
EP2146210A1 (en)	2008-04-07	2010-01-20	Arena Pharmaceuticals, Inc.	Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
AR077642A1 (en)	2009-07-09	2011-09-14	Arena Pharm Inc	METABOLISM MODULATORS AND THE TREATMENT OF DISORDERS RELATED TO THE SAME
WO2011127051A1 (en)	2010-04-06	2011-10-13	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
MX2013003184A (en)	2010-09-22	2013-06-07	Arena Pharm Inc	Modulators of the gpr119 receptor and the treatment of disorders related thereto.
WO2012135570A1 (en)	2011-04-01	2012-10-04	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145361A1 (en)	2011-04-19	2012-10-26	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140051714A1 (en)	2011-04-22	2014-02-20	Arena Pharmaceuticals, Inc.	Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145603A1 (en)	2011-04-22	2012-10-26	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170702A1 (en)	2011-06-08	2012-12-13	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en)	2011-10-12	2013-04-18	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2014074668A1 (en)	2012-11-08	2014-05-15	Arena Pharmaceuticals, Inc.	Modulators of gpr119 and the treatment of disorders related thereto
CA2979033A1 (en)	2015-03-09	2016-09-15	Intekrin Therapeutics, Inc.	Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
CN110996951A (en)	2017-04-03	2020-04-10	科赫罗斯生物科学股份有限公司	PPARγ agonists for the treatment of progressive supranuclear palsy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW492957B (en) *	1996-11-07	2002-07-01	Novartis Ag	N-substituted 2-cyanopyrrolidnes
TWI243162B (en) *	2000-11-10	2005-11-11	Taisho Pharmaceutical Co Ltd	Cyanopyrrolidine derivatives
US7183290B2 (en) *	2001-06-27	2007-02-27	Smithkline Beecham Corporation	Fluoropyrrolidines as dipeptidyl peptidase inhibitors
DE60222667T2 (en) *	2001-06-27	2008-07-17	Smithkline Beecham Corp.	FLUORPYRROLIDINES AS DIPEPTIDYLPEPTIDASE INHIBITORS

2003
- 2003-05-09 JP JP2004508532A patent/JPWO2003095425A1/en not_active Withdrawn
- 2003-05-09 AU AU2003235913A patent/AU2003235913A1/en not_active Abandoned
- 2003-05-09 WO PCT/JP2003/005813 patent/WO2003095425A1/en not_active Ceased

Also Published As

Publication number	Publication date
JPWO2003095425A1 (en)	2005-09-15
WO2003095425A1 (en)	2003-11-20

Publication	Publication Date	Title
AU2003211362A1 (en)	2003-09-09	N-hydroxycarboxamide derivative
AU2002335152A1 (en)	2003-09-04	Robot-phone
AU2003235913A1 (en)	2003-11-11	Cyanopyrrolidine derivatives
AU2003301968A1 (en)	2004-06-03	4-aminomethyl-1-aryl-cyclohexylamine derivatives
AU2003273885A1 (en)	2004-04-23	Morpholine-bridged indazole derivatives
AU2003278369A1 (en)	2004-06-07	3-cyano-quinoline derivatives
AU2003296564A1 (en)	2004-06-03	4-hydroxymethyl-1-aryl-cyclohexylamine derivatives
AU2003222659A1 (en)	2003-11-03	23-o-substituted 5-o-mycaminosyltylonide derivatives
AU2003234131A1 (en)	2003-11-03	5-o-mycaminosyltylonide derivatives
AU2003257637A1 (en)	2004-03-11	Proline derivatives
AU2002367810A1 (en)	2003-11-10	Bis-transition-metal-chelate-probes
AU2003238180A1 (en)	2003-12-31	2-naphtamide derivatives
AU2003273398A1 (en)	2004-04-30	Aroyl-piperidine derivatives
AU2002249639A1 (en)	2003-10-27	Pyranocoumarin derivatives
AU2003288012A1 (en)	2004-06-15	Isothiazolyl-benzoxazine derivatives
AU2003284704A1 (en)	2004-06-23	Substituted 1h-pyridine-2-one derivatives
AU2002318053A1 (en)	2004-02-02	Suplier
AU2002368348A1 (en)	2004-06-03	Electrosomatogram
AU2003243397A1 (en)	2003-12-19	Homo-camptothecin derivatives
AU2002341221A1 (en)	2004-04-19	Honey-brandy
AU2002348964A1 (en)	2004-01-19	Snowbike
AU2002344387A1 (en)	2003-12-22	Multifunction-pillow
HK1076608A (en)	2006-01-20	Propargyl-trifluoromethoxy-amino-benzothiazole derivatives
AU2003284572A1 (en)	2004-06-18	2-oxoindoline derivatives
AU2002100957A4 (en)	2003-06-12	Sluggit

Legal Events

Date	Code	Title	Description
2005-01-27	MK6	Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase
2009-12-10	TH	Corrigenda	Free format text: IN VOL 18, NO 2, PAGE(S) 590 UNDER THE HEADING APPLICATIONS OPI - NAME INDEX UNDER THE NAME TAISHO PHARMACEUTICAL CO., LTD., APPLICATION NO. 2003235913, UNDER INID (43) CORRECT THE PUBLICATION DATE TO READ 24.11.2003